Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

Ken Ei Sada, Masayoshi Harigai, Koichi Amano, Tatsuya Atsumi, Shouichi Fujimoto, Yukio Yuzawa, Yoshinari Takasaki, Shogo Banno, Takahiko Sugihara, Masaki Kobayashi, Joichi Usui, Kunihiro Yamagata, Sakae Homma, Hiroaki Dobashi, Naotake Tsuboi, Akihiro Ishizu, Hitoshi Sugiyama, Yasunori Okada, Yoshihiro Arimura, Seiichi MatsuoHirofumi Makino

研究成果: Article

8 引用 (Scopus)

抄録

Objective: To compare disease severity classification systems for six-month outcome prediction in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: Patients with newly diagnosed AAV from 53 tertiary institutions were enrolled. Six-month remission, overall survival, and end-stage renal disease (ESRD)-free survival were evaluated. Results: According to the European Vasculitis Study Group (EUVAS)-defined disease severity, the 321 enrolled patients were classified as follows: 14, localized; 71, early systemic; 170, generalized; and 66, severe disease. According to the rapidly progressive glomerulonephritis (RPGN) clinical grading system, the patients were divided as follows: 60, grade I; 178, grade II; 66, grade III; and 12, grade IV. According to the Five-Factor Score (FFS) 2009, 103, 109, and 109 patients had ≤1, 2, and ≥3 points, respectively. No significant difference in remission rates was found in any severity classification. The overall and ESRD-free survival rates significantly differed between grades I/II, III, and IV, regardless of renal involvement. Severe disease was a good predictor of six-month overall and ESRD-free survival. The FFS 2009 was useful to predict six-month ESRD-free survival but not overall survival. Conclusions: The RPGN grading system was more useful to predict six-month overall and ESRD-free survival than the EUVAS-defined severity or FFS 2009.

元の言語English
ページ(範囲)730-737
ページ数8
ジャーナルModern Rheumatology
26
発行部数5
DOI
出版物ステータスPublished - 02-09-2016

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
Disease-Free Survival
Chronic Kidney Failure
Cohort Studies
Glomerulonephritis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Survival
Survival Rate
Kidney

All Science Journal Classification (ASJC) codes

  • Rheumatology

これを引用

Sada, Ken Ei ; Harigai, Masayoshi ; Amano, Koichi ; Atsumi, Tatsuya ; Fujimoto, Shouichi ; Yuzawa, Yukio ; Takasaki, Yoshinari ; Banno, Shogo ; Sugihara, Takahiko ; Kobayashi, Masaki ; Usui, Joichi ; Yamagata, Kunihiro ; Homma, Sakae ; Dobashi, Hiroaki ; Tsuboi, Naotake ; Ishizu, Akihiro ; Sugiyama, Hitoshi ; Okada, Yasunori ; Arimura, Yoshihiro ; Matsuo, Seiichi ; Makino, Hirofumi. / Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. :: Modern Rheumatology. 2016 ; 巻 26, 番号 5. pp. 730-737.
@article{756ad989a2d64113933c40e5312c543c,
title = "Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study",
abstract = "Objective: To compare disease severity classification systems for six-month outcome prediction in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: Patients with newly diagnosed AAV from 53 tertiary institutions were enrolled. Six-month remission, overall survival, and end-stage renal disease (ESRD)-free survival were evaluated. Results: According to the European Vasculitis Study Group (EUVAS)-defined disease severity, the 321 enrolled patients were classified as follows: 14, localized; 71, early systemic; 170, generalized; and 66, severe disease. According to the rapidly progressive glomerulonephritis (RPGN) clinical grading system, the patients were divided as follows: 60, grade I; 178, grade II; 66, grade III; and 12, grade IV. According to the Five-Factor Score (FFS) 2009, 103, 109, and 109 patients had ≤1, 2, and ≥3 points, respectively. No significant difference in remission rates was found in any severity classification. The overall and ESRD-free survival rates significantly differed between grades I/II, III, and IV, regardless of renal involvement. Severe disease was a good predictor of six-month overall and ESRD-free survival. The FFS 2009 was useful to predict six-month ESRD-free survival but not overall survival. Conclusions: The RPGN grading system was more useful to predict six-month overall and ESRD-free survival than the EUVAS-defined severity or FFS 2009.",
author = "Sada, {Ken Ei} and Masayoshi Harigai and Koichi Amano and Tatsuya Atsumi and Shouichi Fujimoto and Yukio Yuzawa and Yoshinari Takasaki and Shogo Banno and Takahiko Sugihara and Masaki Kobayashi and Joichi Usui and Kunihiro Yamagata and Sakae Homma and Hiroaki Dobashi and Naotake Tsuboi and Akihiro Ishizu and Hitoshi Sugiyama and Yasunori Okada and Yoshihiro Arimura and Seiichi Matsuo and Hirofumi Makino",
year = "2016",
month = "9",
day = "2",
doi = "10.3109/14397595.2016.1140274",
language = "English",
volume = "26",
pages = "730--737",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "5",

}

Sada, KE, Harigai, M, Amano, K, Atsumi, T, Fujimoto, S, Yuzawa, Y, Takasaki, Y, Banno, S, Sugihara, T, Kobayashi, M, Usui, J, Yamagata, K, Homma, S, Dobashi, H, Tsuboi, N, Ishizu, A, Sugiyama, H, Okada, Y, Arimura, Y, Matsuo, S & Makino, H 2016, 'Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study', Modern Rheumatology, 巻. 26, 番号 5, pp. 730-737. https://doi.org/10.3109/14397595.2016.1140274

Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. / Sada, Ken Ei; Harigai, Masayoshi; Amano, Koichi; Atsumi, Tatsuya; Fujimoto, Shouichi; Yuzawa, Yukio; Takasaki, Yoshinari; Banno, Shogo; Sugihara, Takahiko; Kobayashi, Masaki; Usui, Joichi; Yamagata, Kunihiro; Homma, Sakae; Dobashi, Hiroaki; Tsuboi, Naotake; Ishizu, Akihiro; Sugiyama, Hitoshi; Okada, Yasunori; Arimura, Yoshihiro; Matsuo, Seiichi; Makino, Hirofumi.

:: Modern Rheumatology, 巻 26, 番号 5, 02.09.2016, p. 730-737.

研究成果: Article

TY - JOUR

T1 - Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

AU - Sada, Ken Ei

AU - Harigai, Masayoshi

AU - Amano, Koichi

AU - Atsumi, Tatsuya

AU - Fujimoto, Shouichi

AU - Yuzawa, Yukio

AU - Takasaki, Yoshinari

AU - Banno, Shogo

AU - Sugihara, Takahiko

AU - Kobayashi, Masaki

AU - Usui, Joichi

AU - Yamagata, Kunihiro

AU - Homma, Sakae

AU - Dobashi, Hiroaki

AU - Tsuboi, Naotake

AU - Ishizu, Akihiro

AU - Sugiyama, Hitoshi

AU - Okada, Yasunori

AU - Arimura, Yoshihiro

AU - Matsuo, Seiichi

AU - Makino, Hirofumi

PY - 2016/9/2

Y1 - 2016/9/2

N2 - Objective: To compare disease severity classification systems for six-month outcome prediction in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: Patients with newly diagnosed AAV from 53 tertiary institutions were enrolled. Six-month remission, overall survival, and end-stage renal disease (ESRD)-free survival were evaluated. Results: According to the European Vasculitis Study Group (EUVAS)-defined disease severity, the 321 enrolled patients were classified as follows: 14, localized; 71, early systemic; 170, generalized; and 66, severe disease. According to the rapidly progressive glomerulonephritis (RPGN) clinical grading system, the patients were divided as follows: 60, grade I; 178, grade II; 66, grade III; and 12, grade IV. According to the Five-Factor Score (FFS) 2009, 103, 109, and 109 patients had ≤1, 2, and ≥3 points, respectively. No significant difference in remission rates was found in any severity classification. The overall and ESRD-free survival rates significantly differed between grades I/II, III, and IV, regardless of renal involvement. Severe disease was a good predictor of six-month overall and ESRD-free survival. The FFS 2009 was useful to predict six-month ESRD-free survival but not overall survival. Conclusions: The RPGN grading system was more useful to predict six-month overall and ESRD-free survival than the EUVAS-defined severity or FFS 2009.

AB - Objective: To compare disease severity classification systems for six-month outcome prediction in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: Patients with newly diagnosed AAV from 53 tertiary institutions were enrolled. Six-month remission, overall survival, and end-stage renal disease (ESRD)-free survival were evaluated. Results: According to the European Vasculitis Study Group (EUVAS)-defined disease severity, the 321 enrolled patients were classified as follows: 14, localized; 71, early systemic; 170, generalized; and 66, severe disease. According to the rapidly progressive glomerulonephritis (RPGN) clinical grading system, the patients were divided as follows: 60, grade I; 178, grade II; 66, grade III; and 12, grade IV. According to the Five-Factor Score (FFS) 2009, 103, 109, and 109 patients had ≤1, 2, and ≥3 points, respectively. No significant difference in remission rates was found in any severity classification. The overall and ESRD-free survival rates significantly differed between grades I/II, III, and IV, regardless of renal involvement. Severe disease was a good predictor of six-month overall and ESRD-free survival. The FFS 2009 was useful to predict six-month ESRD-free survival but not overall survival. Conclusions: The RPGN grading system was more useful to predict six-month overall and ESRD-free survival than the EUVAS-defined severity or FFS 2009.

UR - http://www.scopus.com/inward/record.url?scp=84983783201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983783201&partnerID=8YFLogxK

U2 - 10.3109/14397595.2016.1140274

DO - 10.3109/14397595.2016.1140274

M3 - Article

C2 - 26873424

AN - SCOPUS:84983783201

VL - 26

SP - 730

EP - 737

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 5

ER -